88 related articles for article (PubMed ID: 28918212)
1. An α-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients.
Eguchi K; Komori T; Saito T; Hoshide S; Kario K
J Electrocardiol; 2018; 51(1):21-26. PubMed ID: 28918212
[TBL] [Abstract][Full Text] [Related]
2. α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.
Shimabukuro M; Tanaka A; Sata M; Dai K; Shibata Y; Inoue Y; Ikenaga H; Kishimoto S; Ogasawara K; Takashima A; Niki T; Arasaki O; Oshiro K; Mori Y; Ishihara M; Node K;
Cardiovasc Diabetol; 2017 Jul; 16(1):86. PubMed ID: 28683829
[TBL] [Abstract][Full Text] [Related]
3. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
4. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
6. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
8. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
[TBL] [Abstract][Full Text] [Related]
9. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Fehmann HC
Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357
[TBL] [Abstract][Full Text] [Related]
10. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
[TBL] [Abstract][Full Text] [Related]
11. Treatment with the α-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes.
Mochizuki K; Fukaya N; Tanaka Y; Fuchigami M; Goda T
Metabolism; 2011 Nov; 60(11):1560-5. PubMed ID: 21550076
[TBL] [Abstract][Full Text] [Related]
12. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
[No Abstract] [Full Text] [Related]
13. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
[TBL] [Abstract][Full Text] [Related]
14. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
15. The alpha-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic beta-cells in OLETF rats.
Fukaya N; Mochizuki K; Tanaka Y; Kumazawa T; Jiuxin Z; Fuchigami M; Goda T
Eur J Pharmacol; 2009 Dec; 624(1-3):51-7. PubMed ID: 19818342
[TBL] [Abstract][Full Text] [Related]
16. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
Scott AR; Tattersall RB
Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Kishimoto M; Noda M
Clin Drug Investig; 2015 Feb; 35(2):141-7. PubMed ID: 25511640
[TBL] [Abstract][Full Text] [Related]
18. Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion.
Lee EY; Kaneko S; Jutabha P; Zhang X; Seino S; Jomori T; Anzai N; Miki T
J Endocrinol; 2015 Mar; 224(3):205-14. PubMed ID: 25486965
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
Aoki K; Nakajima S; Nezu U; Shinoda K; Terauchi Y
Diabetes Obes Metab; 2008 Sep; 10(10):970-2. PubMed ID: 18721256
[TBL] [Abstract][Full Text] [Related]
20. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
Willms B; Lübke D; Ahrens K; Arends J
Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
